Last updated: February 28, 2026
What is the drug associated with NDC 72888-0059?
The NDC 72888-0059 corresponds to Siponimod (Mayzent). It is an oral medication approved by the FDA in March 2019 for treating relapsing forms of multiple sclerosis (MS), including active secondary progressive MS.
Market Overview
Current Market Size
The global multiple sclerosis (MS) treatment market reached approximately USD 24.7 billion in 2022. Within this, oral disease-modifying therapies (DMTs) constitute a significant share, estimated at USD 12 billion.
Key Competitors
- Aubagio (Teriflunomide)
- Gilenya (Fingolimod)
- Mayzent (Siponimod)
- Ozanimod (Zeposia)
Market Position of Mayzent
Mayzent holds a niche in secondary progressive MS (SPMS), a subset of the broader MS market with about 10-20% of MS patients diagnosed at this stage. Since its launch, Mayzent's market penetration remains limited relative to first-line agents like Gilenya but benefits from the FDA's expanded indication.
Sales Performance
In 2022, Mayzent generated approximately USD 350 million in global sales, a figure expected to grow as MS diagnoses increase, and prescriber awareness expands.
Regulatory and Reimbursement Landscape
- Approved in the U.S., EU, and select Asian markets.
- Reimbursement policies generally favor brand-name DMTs, though pricing pressures exist.
Pricing Analysis
Current Pricing
- U.S. Wholesale Acquisition Cost (WAC): USD 87,600 annually per patient (approx. USD 7,300 monthly), based on a 28-day supply.
- Average Wholesale Price (AWP): Approximately USD 105,120 annually.
Pricing in Europe and Asia tends to be 10-20% lower, reflecting regional pricing strategies.
Comparison with Similar Drugs
| Drug |
Approximate Annual Price |
Indication |
Market Share (2022) |
| Gilenya |
USD 86,000 |
Relapsing MS |
Largest among oral DMTs |
| Aubagio |
USD 54,000 |
Relapsing MS |
Moderate share |
| Ozanimod |
USD 70,000 |
Relapsing MS |
Growing presence |
Mayzent's pricing aligns closely with Gilenya, targeting a similar patient demographic with a focus on secondary progressive MS.
Price Projection Outlook
Short-Term (2023-2025)
- Stable Pricing: Price levels will likely remain steady, with minor adjustments for inflation and reimbursement pressures.
- Potential Discounts: Payer negotiations may lead to volume-based discounts, especially in institutional segments.
Medium-Term (2025-2030)
- Gradual Price Decline: Anticipated 3-5% annual reduction driven by biosimilar and generic competition for competing drugs.
- Market Expansion: Broader prescribing for earlier stages or off-label uses could increase volume, offsetting price declines.
Long-Term Trends (2030+)
- Pricing Pressure: Increased biosimilar entries and value-based pricing models could reduce Mayzent's price by 20-30%.
- Market Saturation: A plateau in MS diagnoses and stable market share could limit revenue growth.
Key Factors Affecting Price and Market
- Patent Status: Patent expiration prospects around 2028-2030 could facilitate biosimilar entry and price erosion.
- Regulatory Approvals: Expanded indications could increase sales volume.
- Reimbursement Policies: Shifts toward value-based care may influence net pricing.
- Competitive Dynamics: New entrants or better-efficacy therapies could suppress prices.
Summary
| Parameter |
Current Status |
Future Projection |
| Market share |
Small but growing niche in MS treatment |
Gradually increases with broader use |
| Pricing (USD/year) |
Approx. USD 87,600 (WAC) |
Remains stable then declines 3-5% annually after 2025 |
| Total sales (2022) |
USD 350 million |
Expected to double by 2028 with market expansion |
Key Takeaways
- Mayzent is a key player in secondary progressive MS, with stable pricing approaching USD 87,600 annually.
- The market for MS therapies is expanding, driven by increasing diagnoses and later-stage treatment needs.
- Price pressures from biosimilars and competitive therapies are anticipated over the next 5-10 years.
- Long-term pricing will reflect regional policies, patent status, and evolving reimbursement models.
FAQs
1. Will the price of Mayzent decrease significantly post-patent expiration?
Yes. Patent expiry around 2028-2030 could lead to biosimilar competition, likely reducing prices by 20-30%.
2. How does Mayzent compare to other MS drugs in terms of cost?
It costs roughly USD 87,600 annually, similar to Gilenya but higher than Aubagio, which is approximately USD 54,000.
3. Are there generic options for Mayzent?
No, as of now, no generic versions exist. Patent protections prevent generic entry until approximately 2028-2030.
4. What regional pricing differences exist?
In the U.S., prices are highest due to reimbursement structures. European prices are typically 10-20% lower. Asia markets often see further discounts.
5. What factors could impact future sales of Mayzent?
Market expansion to earlier MS stages, approval for additional indications, competitor biosimilars, and pricing policies.
Sources
[1] IBISWorld. (2023). Multiple Sclerosis Treatment Market Analysis.
[2] IQVIA. (2022). Global MS Drugs Sales Data.
[3] FDA. (2019). Mayzent (Siponimod) Approval Notice.
[4] EvaluatePharma. (2022). Market Forecasts for MS Therapies.
[5] FDA. (2023). Patent Status and Biosimilar Guidelines.
